SCHEDULE: Armistice Capital Reduces Stake in ZyVersa Therapeutics

Armistice Capital, LLC reports a decreased ownership stake in ZyVersa Therapeutics, Inc., falling below the 5% threshold.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, reporting their ownership stake in ZyVersa Therapeutics, Inc.
• As of June 30, 2025, Armistice Capital, LLC and Steven Boyd each beneficially own 416,800 shares of ZyVersa Therapeutics' common stock.
• This represents 4.99% of the outstanding shares, a decrease from their previous filing.
• Armistice Capital, LLC has sole voting power over 0 shares and shared voting power over 416,800 shares.
• Armistice Capital, LLC has sole dispositive power over 0 shares and shared dispositive power over 416,800 shares.
• Steven Boyd, as the Managing Member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund.

Sentiment

Score: 4

Explanation: The decrease in ownership suggests a slightly negative sentiment, but the filing states the shares are held in the ordinary course of business.

Positives

• The filing indicates that the securities were acquired and are held in the ordinary course of business.
• The securities were not acquired for the purpose of changing or influencing the control of ZyVersa Therapeutics.

Negatives

• Armistice Capital's decreased ownership stake could be interpreted negatively by the market.

Risks

• The filing does not explicitly mention risks, but a decreased ownership stake by a significant shareholder could introduce uncertainty.

Future Outlook

The filing does not contain any specific forward-looking statements regarding ZyVersa Therapeutics' future performance or Armistice Capital's future investment intentions.

Management Comments

• There are no direct quotes from ZyVersa Therapeutics' management in this filing.
• Armistice Capital disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

Schedule 13G filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency regarding significant ownership positions. Changes in ownership can reflect investor sentiment and portfolio adjustments.

Comparison to Industry Standards

• Comparable filings would include other Schedule 13G filings for ZyVersa Therapeutics or similar biotechnology companies.
• Analyzing ownership trends across the biotechnology sector can provide insights into overall investor sentiment.
• Comparing Armistice Capital's investment strategy with that of other hedge funds specializing in healthcare can offer a broader perspective.

Stakeholder Impact

• Shareholders: The decreased ownership stake could create uncertainty and potentially impact the stock price.
• Employees: No direct impact is apparent from this filing.
• Customers: No direct impact is apparent from this filing.
• Suppliers: No direct impact is apparent from this filing.
• Creditors: No direct impact is apparent from this filing.

Next Steps

• Monitor future filings by Armistice Capital to track any further changes in their ownership position.
• Analyze ZyVersa Therapeutics' upcoming financial reports and announcements for any factors that may have influenced Armistice Capital's decision.

Key Dates

Recommendation

The decrease in ownership by Armistice Capital is a slightly negative signal, but not enough to warrant a sell recommendation. Further monitoring of the company's performance and future filings is recommended before making any changes to investment positions.

Keywords

Schedule 13G, ZyVersa Therapeutics, Armistice Capital, Steven Boyd, Ownership, Beneficial Ownership, Common Stock, SEC Filing